Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 1
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH, Nguyen V, Arnould L, Viola F, Zarranz-Ventura J, Barthelmes D, Creuzot-Garcher C, Gillies M; Fight Retinal Blindness! Study Group. Gabrielle PH, et al. Ophthalmol Retina. 2022 Nov;6(11):1044-1053. doi: 10.1016/j.oret.2022.05.008. Epub 2022 May 16. Ophthalmol Retina. 2022. PMID: 35589075 Free article.
Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.
García-Quintanilla L, Almuiña-Varela P, Maroñas O, Gil-Rodriguez A, Rodríguez-Cid MJ, Gil-Martinez M, Abraldes MJ, Gómez-Ulla de Irazazabal F, González-Barcia M, Mondelo-Garcia C, Cruz R, Estany-Gestal A, Fernández-Rodríguez M, Fernández-Ferreiro A. García-Quintanilla L, et al. Among authors: almuina varela p. Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):34. doi: 10.1167/iovs.64.13.34. Invest Ophthalmol Vis Sci. 2023. PMID: 37862026 Free PMC article.
Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, Lavid de Los Mozos FJ, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, Gonzalez-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J; Writing Committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group. Izquierdo-Serra J, et al. Ophthalmol Retina. 2024 Apr;8(4):350-359. doi: 10.1016/j.oret.2023.10.022. Epub 2023 Nov 2. Ophthalmol Retina. 2024. PMID: 37924946
Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.
Almuiña-Varela P, García-Quintanilla L, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, Estany-Gestal A, Alcántara-Espinosa JM, Fernández-Rodríguez M, Fernández-Ferreiro A. Almuiña-Varela P, et al. Pharmaceuticals (Basel). 2024 Jan 25;17(2):157. doi: 10.3390/ph17020157. Pharmaceuticals (Basel). 2024. PMID: 38399372 Free PMC article.
The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.
García-Quintanilla L, Almuiña-Varela P, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, González-Barcia M, Mondelo-García C, Estany-Gestal A, Otero-Espinar FJ, Fernández-Rodríguez M, Fernández-Ferreiro A. García-Quintanilla L, et al. Among authors: almuina varela p. Pharmaceutics. 2024 Jan 13;16(1):105. doi: 10.3390/pharmaceutics16010105. Pharmaceutics. 2024. PMID: 38258115 Free PMC article.